Eli Lilly and Company has started construction on a new manufacturing campus in Pennsylvania’s Lehigh Valley, advancing a major expansion of its U.S. production footprint. The company has broken ground on a $3.5 billion facility in Fogelsville, Pennsylvania, that will be dedicated to producing injectable medicines and devices. This project is one of 10 new U.S. manufacturing sites Eli Lilly has announced since 2020 and is among four focused specifically on injectable therapies.
The Lehigh Valley campus is part of Eli Lilly’s broader $50 billion initiative to expand medicine manufacturing capacity in the United States. According to the company, the Fogelsville facility is intended to add production capability for the next generation of treatments. While specific building details were not disclosed, the investment highlights the role of advanced pharmaceutical manufacturing in the region’s industrial base.
The project is expected to have a sizable employment impact once fully realized. Eli Lilly anticipates creating 850 high-wage permanent jobs at the new facility, spanning a range of technical, operational, and support functions. During the construction and commissioning phase, the company expects the project to support approximately 2,000 construction jobs as the campus is built and brought online.
The new site is expected to be operational by 2031, positioning the Lehigh Valley as a long-term hub in Eli Lilly’s manufacturing network. The extended development timeline reflects the scale and complexity of building out specialized pharmaceutical production infrastructure and bringing it into full regulatory and operational readiness.
Pennsylvania Governor Josh Shapiro framed the groundbreaking as a milestone for the state’s life sciences ecosystem. He noted that the project underscores the strength of Pennsylvania’s life sciences sector and aligns with his administration’s focus on advancing innovation, supporting economic growth, and creating well-paying jobs across the Commonwealth.
The announcement also reinforces the Lehigh Valley’s role within the broader regional economy as a destination for large-scale life sciences and advanced manufacturing investment, complementing its existing industrial and logistics activity.
